





Hypothyroidism in children





Contributors:

- **Prof. P. Raghupathy**
- **Prof. Mahesh Maheshwari**
- **Dr. Amarnath Kulkarni**
- **Dr. Mugdha Todkar**
- **Dr. Vaishnavi Agrawal**

Synthesis of thyroid hormones







T3 Production


- **Only 20% of T3 is directly produced in thyroid gland**
- **Remaining 80% of T3 produced is formed by 5'-deiodination of T4 in extrathyroidal tissues**
- **Extrathyroidal T3 production:**
 - Sites: Liver, kidney**
 - Other sites: Muscle, brain, pituitary, skin, placenta**

Serum Binding Proteins

More than 99.95% of T4 and 99.5% of the T3 in serum are bound to several serum proteins:

- **Thyroxine-binding globulin (TBG)**
- **Albumin**
- **Lipoproteins**

Regulation of Thyroid Hormones



Normal thyroid physiology in the fetus

- First half of pregnancy



T4 in fetus is of maternal origin


- Second half of pregnancy



T4 production switches over from maternal to fetal origin

**Maternal T4
partially protects
a hypothyroid
fetus in-utero.**

Postnatal thyroid function



Brook's clinical Pediatric Endocrinology, 6th Edition, 2009

Serum TSH rises abruptly within 30 to 60 mins after delivery due to:

- Stress during labor
- Clamping of umbilical cord
- Exposure to cold environment outside the uterus

T4 Surge is seen on day 1-2

MEAN ± SD FOR TSH AND T4 OF PRETERM AND TERM INFANTS 0-28 DAYS

Age ± SD	Cord (Day 0)	Day 7	Day 14	Day 28
T₄ (mcg/dL)				
23–27*	5.44 ± 2.02	4.04 ± 1.79	4.74 ± 2.56	6.14 ± 2.33
28–30	6.29 ± 2.02	6.29 ± 2.10	6.60 ± 2.25	7.46 ± 2.33
31–34	7.61 ± 2.25	9.40 ± 3.42	9.09 ± 3.57	8.94 ± 2.95
>37	9.17 ± 1.94	12.67 ± 2.87	10.72 ± 1.40	9.71 ± 2.18
FT₄ (ng/dL)				
23–27	1.28 ± 0.41	1.47 ± 0.56	1.45 ± 0.51	1.50 ± 0.43
28–30	1.45 ± 0.43	1.82 ± 0.66	1.65 ± 0.44	1.71 ± 0.43
31–34	1.49 ± 0.33	2.14 ± 0.57	1.96 ± 0.43	1.88 ± 0.46
>37	1.41 ± 0.39	2.70 ± 0.57	2.03 ± 0.28	1.65 ± 0.34
TSH (mIU/L)				
23–27	6.80 ± 2.90	3.50 ± 2.60	3.90 ± 2.70	3.80 ± 4.70
28–30	7.00 ± 3.70	3.60 ± 2.50	4.90 ± 11.2	3.60 ± 2.50
31–34	7.90 ± 5.20	3.60 ± 4.80	3.80 ± 9.30	3.50 ± 3.40
>37	6.70 ± 4.80	2.60 ± 1.80	2.50 ± 2.00	1.80 ± 0.90

*Weeks gestational age

Williams FL, et al. Developmental trends in cord and postpartum serum thyroid hormones in preterm infants. *J Clin Endocrinol Metab.* 2004;89:5314-5320.



AGE-BASED NORMAL VALUES FOR ROUTINE THYROID FUNCTION TESTS¹⁴

Age	Free T ₄	TSH			Reverse T ₃	TBG
	(ng/dL)	(mIU/L)	T ₄ (mcg/dL)	T ₃ (ng/dL)	(ng/dL)	(mcg/mL)
Day of birth	0.94–4.39	2.43–24.3	5.85–18.68	19.53–266.26	19.53–358.70	19.17–44.7
1 wk	0.96–4.08	0.58–5.58*	5.90–18.58	20.83–265.61	19.53–338.52	19.16–44.68
1 mo	1.00–3.44	0.58–5.57*	6.06–18.27	25.39–264.31	19.53–283.84	19.12–44.59
3 mo	1.04–2.86	0.58–5.57*	6.39–17.66	36.46–259.75	19.53–197.90	19.02–44.35
6 mo	1.07–2.44	0.58–5.56*	6.75–17.04	51.43–252.59	19.53–137.36	18.87–44
1 yr	1.10–2.19	0.57–5.54	7.10–16.16	74.87–240.87	18.23–85.93	18.56–43.28
2 yr	1.11–2.05	0.57–5.51	7.16–14.98	103.51–228.50	16.93–55.99	17.94–41.82
5 yr	1.08–1.93	0.56–5.41	6.39–12.94	131.50–212.23	13.02–35.81	16–37.3
8 yr	1.04–1.87	0.55–5.31	5.72–11.71	130.85–202.46	11.72–30.60	14.2–33.09
12 yr	0.99–1.81	0.53–5.16	5.08–10.58	119.78–192.70	11.07–27.99	12.54–29.24
15 yr	1.03–1.77	0.52–5.05	4.84–10.13	110.02–184.88	10.42–27.34	11.96–27.89
18 yr	0.93–1.73	0.51–4.93		101.56–179.03	10.42–26.04	

Lem AJ, et al. Serum thyroid hormone levels in healthy children from birth to adulthood and in short children born small for gestational age. *J Clin Endocrinol Metab.* 2012;97:3170-3178.

How is hypothyroidism classified?

HYPOTHYROIDISM



CONGENITAL

Hypothyroidism
present since birth


ACQUIRED

Hypothyroidism
develops during
childhood



Congenital hypothyroidism (CH)

First things first!!!



How does CH present?

Trans-placental passage of maternal T4

No obvious manifestations at birth

Large anterior and posterior fontanelles with open sutures

Umbilical hernia

Large tongue

Prolonged jaundice

Dry skin

Constipation

Excessive sleep

Dys-morphic facies

Wide nasal bridge

Hypotonia

Presentation of CH, if untreated by 3-6 months of age

- **Delayed developmental milestones progressing to disability**
- **Short stature (short extremities)**
- **Delayed dentition**
- **Hypotonia**
- **Myxedema facies (dysmorphic facies):**
 - **Narrow palpebral fissures with swollen eyelids**
 - **Dry and coarse skin**
 - **Coarse hair**
- **Infant Hercules; Kocher-Debre-Semelaigne (KDS) syndrome**

CH missed at birth, presenting later



Why is early detection of CH important?



Most common preventable cause of intellectual disability
Prevalence of CH : In World- 1 : 3,000 to 1 : 4,000
In India - 1 : 800 to 1 : 1,500



Near normal outcomes are seen, if CH diagnosed and treated
before 2 weeks of age
Early detection is recommended to prevent neurodevelopmental
disability and to optimize the developmental outcomes



Less than 5% newborns and only up to 10% may show
symptoms in the first month of life



A day's delay in the diagnosis = a percent decrease in the
neurodevelopment (DQ/IQ)

Newborn screening (NBS) - which sample?




**Cord blood
(Not affected
by TSH surge)**



**Postnatal:
Heel prick
(Filter paper)**



**Postnatal:
Peripheral
venous sample**



NBS: Which sample?

Cord blood

Advantages:

TSH surge is spared *
Useful in early hospital discharge
No prick for newborn

Disadvantages:

Requirement of round the clock
personnel

Caution

Blood collection: Placental end of
cord from umbilical vein
Cord blood TSH <25 μ IU/mL

Postnatal sample (Heel prick)

Advantages:

Screening of other conditions
Home delivered babies


Disadvantages:

Postnatal TSH surge
Requirement of special
reagents and equipment and
trained personnel

Caution:

Error free blood spots

* TSH surge is not
spared always—
to be interpreted
appropriately
for deciding normal
range



Site for Heel prick

NBS: When to test?

- **Routine screening at 48-72 hours, NOT later than 5 days after birth**
- **High-risk neonates such as Preterm/LBW/VLBW/Down syndrome/
Sick neonates admitted in NICU - second screening may be needed
at 4 weeks of age**

**All newborns, including those treated in the NICU
should be uniformly screened for CH without fail**

NBS – When to test?

**Preterm/
SGA**

- **48-72 hrs after birth (as for term neonates)**

Sick newborn

- **Before 7 days of life OR at discharge – whichever is earlier**

CH screen: Which test?

T4 based

Identifies primary
and central
hypothyroidism

Higher false
positivity

May miss subclinical
hypothyroidism

TSH based

More sensitive
and specific


Preferred
screening test

May miss central
hypothyroidism




**TSH based
screening is
recommended
in India**

ISPAE Guidelines on Congenital Hypothyroidism screening (2018)



Borderline Thyroid Function Tests*

*Take help from pediatric endocrinologist



Sick euthyroid syndrome

- It refers to changes in thyroid function tests in an inpatient or ICU during critical illness
- Occurs due to transient alterations in the HPT axis
- Presents as:
 - low total T3 and FT3 levels
 - low or normal T4 and TSH levels
- So, when serum TSH is not elevated, the euthyroid sick syndrome should be considered even in patients with known thyroid disease and low serum FT3 or T4 levels
- Most of the times treatment is not required (self-limiting)

Indications for second screening

- Preterm neonates (<37 weeks)
- LBW and VLBW
- Neonates admitted to NICU
- Borderline high TSH & normal T4 during NBS
- Multiple births
- Down syndrome

WHEN?

After 2 weeks of age

OR

2 weeks after the first screening

NBS in preterm neonates

Attenuated TSH surge

- Immature HPT axis

Low T4 & T3

- Loss of maternal T4, immature gland, high type 3 deiodinase activity

Drugs down-regulating TSH secretion

- Steroids, dopamine, topical iodine


Sick euthyroid syndrome

- False negative or positive screen

History & Physical examination

- **Consanguinity, maternal autoimmune thyroid disease, iodine exposure**
- **Gestational age, birth weight, neonatal events**
- **Dysmorphism**
- **Other anomalies (cleft palate, congenital heart disease) & hypotonia**

Role of imaging in CH



- **Identification of etiology of CH (Absent thyroid gland needs: full dose of thyroxine)**
- **Helps in counselling family regarding lifelong replacement**
- **If permanent etiology confirmed initially, it can avoid re-evaluation by interrupting treatment at 3 years of age**

WHY?




- **USG can be done anytime before or after starting treatment (requires expertise)**
- **Tc^{99m} scan should be done before starting treatment or within 7 days**

WHEN?




Role of Imaging (Tc^{99m}) – Cong. Hypothyroidism



Normal Thyroid gland uptake




Hemiagenesis



Ectopic Lingual thyroid




Complete Agenesis



Thyroid Dysmorphogenesis

Other investigations

- **Hearing screen (SNHL, Pendred syndrome)**
- **AP radiograph of knee: Absent lower femoral epiphysis + upper tibial epiphysis (suggests CH)**
- **S. cortisol (in central hypothyroidism to rule out hypopituitarism)**



If serum cortisol levels are low



**Start hydrocortisone prior to thyroxine
to prevent adrenal crisis**

Treatment of CH

- Replacement with Levothyroxine (LT4)
 - Dosage: 10-15 $\mu\text{g}/\text{kg}/\text{day}$
 - Administration: Early in the morning on an empty stomach
- Crush tablet, mix in small quantity of breastmilk/water
- Do not add tablet to formula feeds
- Avoid iron/calcium/vitamins within 3-4 hours of thyroxine

**Counsel the family –
NEVER to stop thyroxine**

Rechecking for permanency of CH

- **Indications**

Suspected transient hypothyroidism

Etiological evaluation (imaging studies) not done at diagnosis

When only low dose of thyroxine is required

Re-evaluation not required in cases of
Permanent CH
(e.g. ectopic thyroid, agenesis)


- **When?**

At 3 years of age

- **How?**


Stop thyroxine for 4 weeks

Recheck TSH and FT4



Monitoring and follow up

- **Investigations: Serum TSH and T4/FT4**
- **After 2 weeks of starting therapy**
- **At 1 month**
- **Subsequent follow up**
 - **Every 2 months till 6 months of age**
 - **Every 3 months from 6 months to 3 years**
 - **Every 3-4 months thereafter till completion of growth and puberty**
- **4 weeks after changing thyroxine dose**
 - **Target FT4 – Upper half of reference range by 2 weeks**
 - **Target TSH – Lower half of normal range by 4 weeks**



Sampling to be done before the thyroxine dose or at least 4 hour after

Follow up

T4 & TSH

Maintain T4 in upper half of normal range

Maintain TSH in lower half of normal range

Growth & puberty

Plotting of height and weight regularly on a growth chart

Adolescents: Tanner staging

Development

Head circumference monitoring

Developmental milestones assessment

IQ assessment when required

Prognosis

- **Early diagnosis and adequate treatment from the 1st week of life results in normal linear growth and development, normal scoring in psychometric testing**
- **Delay in diagnosis, inadequate treatment & poor compliance results in variable degrees of brain damage**

Case scenario

Q. Tanuj, 3-month old boy

Exclusively breastfed infant

C/o Constipation –

- **bowel movement once in 4 days, only after Dulcolax suppository**
- **H/o constipation from 6 weeks of age, passing stools once in 2-3 days**

Earlier, 3-4 stools per day


No treatment sought – grandmother said “no worries”

No newborn thyroid screening was done



Tc^{99m} scan

Sublingual
(ectopic)
thyroid



- Had social smile, no head control, anicteric
- AF wide open, PF open
- Sagittal suture wide, metopic suture open
- Hypothyroid facies; Large tongue, no umbilical hernia
- Tracheal rings easily felt, thyroid not palpable

- S. Total T₄ 1.31 µg/dL (6.0-17.6), S. TSH 351.8 µIU/mL (0.58–5.57),
- Tc^{99m} scan – Sublingual (ectopic) thyroid


- Advised L-thyroxine 37.5 µg OD
- Parents counselled; advised lifelong replacement therapy

Learning points

- 1. Importance of NBS for CH**
- 2. Symptom of constipation when exclusively breastfed, ignored**
- 3. Wide open fontanelles, suture lines not examined**
- 4. Delayed motor development not recognized**

Take home message

**NBS should be
routinely
undertaken in ALL
live newborns to
rule out CH**



**Most common
preventable
cause of
intellectual
disability is CH**

Acquired Hypothyroidism (AH)

Common causes of AH

- **Autoimmune thyroid disease-**

Female (5–15%) : Male (1–5%)*


Hashimoto's thyroiditis (juvenile AH)

Autoimmune polyglandular syndromes type 1 and 2


- **Iodine deficiency**
- **Central hypothyroidism: Trauma, tumour, and tuberculosis**
- **Infectious thyroiditis**
 - Suppurative thyroiditis**
- **Drugs: Anticonvulsants, amiodarone, lithium, chemotherapy, and radiotherapy**
- **Miscellaneous: Post-ablative, post-thyroidectomy, etc.**

*Franco JS, et al. Thyroid disease and autoimmune diseases. In: Anaya JM, et al., editors. Autoimmunity: From Bench to Bedside [Internet]. Bogota (Colombia): El Rosario University Press; 2013 Jul 18. Chapter 30.


Etiology



**Cellular immune
responses**



Humoral immunity



**Immune-susceptible
genes**

Clinical features that suggest the possibility of AH

Sluggishness

Constipation

Hoarseness of voice

Dry rough skin

Cold intolerance

Hypothyroid facies

Weight gain / obesity

Short stature

Delayed DTR

Cardiomyopathy / Effusion

Calf muscle hypertrophy


**Pubertal disorders: puberty delay or precocious
puberty / irregular menses**



**Clinical picture
Myxoedematous facies.**

- **With enlarged testicular volume**
- **Absence of pubic hair.**

Approach to AH



*T3 remains normal in initial stages, as levels do not decline until T4 is very low; Anti-TPO titers= <9.0 IU/ml

Van Wyk Grumbach Syndrome

- Long-standing untreated or poorly controlled hypothyroidism – congenital or acquired
- High levels of TSH
- Isosexual precocity
- Lack of pubic and axillary hair growth
- Delayed bone age / Short stature despite precocity
- Improves rapidly with thyroxine replacement – only treatment required

Boys: Macro-orchidism (Sertoli cell hyperplasia)

Girls: Thelarche (Occasional galactorrhea), vaginal bleeding, ovarian hyperstimulation with large follicles on USG.

May present as a surgical abdomen due to twisted ovarian cyst



Other investigations

- **X-ray for bone age:**
 - **Delayed skeletal maturation in severe/untreated cases**
 - **Stippling of epiphysis may be seen**
- **Thyroid imaging:**
 - **Ultrasonography: Thyroid morphology**
 - **Scintigraphy: Dyshormonogenesis**
- **Screening for associated autoimmune disorders like celiac disease, autoimmune hepatitis, adrenal insufficiency, type 1 diabetes and pernicious anemia**

Role of thyroid ultrasound

Evaluation of the Role of Ultrasonography in Diagnosis of Autoimmune Thyroiditis in Goitrous Children

RK Marwaha, N Tandon, M Ashraf Gani, et al. Indian Pediatr 2008;45; 279



At the same time
Do ultrasound
thyroid gland,
and if need be
FNAC if one
suspects a
nodule

Thyroid USG has a useful, though limited, role in excluding thyroid disease in children.

The sensitivity of echogenicity for the diagnosis of autoimmune thyroiditis in children is less than that reported in adults.


Treatment of AH

- Oral Levothyroxine therapy started based on weight or body surface area
- Early morning, empty stomach, almost the same time every day
100 $\mu\text{g}/\text{m}^2/\text{day}$: as a single dose

OR


Age-dependent dosing

- ✓ 1-3 years: 4-6 $\mu\text{g}/\text{kg}$
- ✓ 3-10 years: 3-5 $\mu\text{g}/\text{kg}$
- ✓ 10-16 years: 2-4 $\mu\text{g}/\text{kg}$



**Goal of treatment:
Euthyroidism
+
Normal growth,
development and puberty**

- **Further dose adjustments with age to maintain TSH and T4/FT4 in range**
- **For long-standing untreated hypothyroidism, thyroxine should be started at lower dose and gradually stepped up over several weeks to reach full dosing**
- **Children with central hypothyroidism require lower doses as compared to those with primary hypothyroidism**




Avoid food half hour before and after medication

Medicines to be stored in cool dry place

Avoid places of high humidity like kitchen and bathroom and direct exposure to sunlight

Avoid calcium and iron supplements for 4 hours after thyroxine administration

Tablets should not be within reach of small children



**DOSE NOT TO BE MISSED,
EVEN ON SICK DAYS**

Blood sampling for monitoring

- **Blood sample for thyroid function (TSH, Total T4, FT4)
should be taken before the morning dose**
- **TSH result is not impacted by the morning thyroxine dose**

Follow-up

- **Clinical monitoring: height, weight, BMI, SMR**
- **Laboratory monitoring:**

FT4 (in upper range of normal), TSH (0.1-5 μ IU/mL)

- **6 weeks after initiation of thyroxine**
- **6 weeks after dose adjustment**
- **Thereafter every 4 monthly**



**Minimum
interval
between
TFT
4-8 weeks**

A. 9y 6m child

TFT -

S. Total thyroxine (TT4) 0.68 $\mu\text{g}/\text{dL}$

S. Free thyroxine (FT4) 0.23 ng/mL

S. Total T3 0.27 ng/mL

S. TSH $> 100 \mu\text{IU}/\text{mL}$

Repeat TSH with double dilution technique - 498.55 $\mu\text{IU}/\text{mL}$

S. Anti-TPO antibody 512 IU/mL


S. Anti-TG antibody 115 IU/mL



Pre-treatment



Post Treatment



Pre-treatment



Post Treatment






Pre-treatment



Post Treatment

Growth after initiation of thyroxine therapy (Catch-up growth)





Goitre

1. Goitre: Acquired Hypothyroidism



2. Goitre: Autoimmune Thyroiditis



Take-Home Messages

Presenting features - Not a goitre always

Easy and inexpensive treatment

Precaution: Thyroxine to be taken on an empty stomach

Gradual increasing of doses – In long-standing hypothyroidism

**Monitor growth and scholastic performance and pubertal status
in adolescents at every visit**

Follow up every 3 monthly to catch early growth faltering

Screen for other autoimmune diseases, if symptomatic

Thank you